Susan Mooberry

Professor

University of Texas Health Science Center at San Antonio

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Susan Mooberry is a Professor at the University of Texas Health Science Center at San Antonio, USA. Her research primarily focuses on cancer biology, particularly the mechanisms of treatment resistance in triple-negative breast cancer and the therapeutic potential of novel compounds. Recent articles highlight her work on microtubule-targeting agents, the cGAS-STING pathway, and the identification of selective inhibitors for cancer subtypes.

Articles (10)

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (4)

Tanja Grkovic

National Cancer Institute

UNITED STATES

View details

Petra Pederson

University of Texas Health Science Center at San Antonio

UNITED STATES

View details

April Risinger

University of Texas Health Science Center at San Antonio

UNITED STATES

View details

Sandra Loesgen

University of Florida

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Susan Mooberry

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

The Microtubule Destabilizer Eribulin Synergizes with STING Agonists to Promote Antitumor Efficacy in Triple-Negative Breast Cancer Models

Design, Synthesis, and Biological Evaluation of 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines as Microtubule Targeting Agents

Altertoxin II, a Highly Effective and Specific Compound against Ewing Sarcoma

Eribulin activates the cGAS-STING pathway via the cytoplasmic accumulation of mtDNA

Yuanhuacine Is a Potent and Selective Inhibitor of the Basal-Like 2 Subtype of Triple Negative Breast Cancer with Immunogenic Potential

Eribulin and Paclitaxel Differentially Alter Extracellular Vesicles and Their Cargo from Triple-Negative Breast Cancer Cells

An Integrated Strategy for the Detection, Dereplication, and Identification of DNA-Binding Biomolecules from Complex Natural Product Mixtures

Correction: Eribulin rapidly inhibits TGF-β-induced Snail expression and can induce Slug expression in a Smad4-dependent manner

CRISPR-Cas9 Genome-Wide Knockout Screen Identifies Mechanism of Selective Activity of Dehydrofalcarinol in Mesenchymal Stem-like Triple-Negative Breast Cancer Cells

Triple-Negative Breast Cancer Cells Exhibit Differential Sensitivity to Cardenolides from Calotropis gigantea

Collaborators (4)

Tanja Grkovic

Petra Pederson

April Risinger

Sandra Loesgen

Make your next move.